Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

Autor: Lb, Grochow, Ek, Rowinsky, Johnson R, Ludeman S, Scott Kaufmann, Fl, Mccabe, Br, Smith, Hurowitz L, DeLisa A, Rc, Donehower

Publikováno v: Europe PubMed Central

Topotecan, a semisynthetic water-soluble analog of camptothecin, is the first topoisomerase I-directed drug to enter clinical trial in the United States in over 20 yr. In this study, 30-min infusions of topotecan were administered daily for 5 days ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::55834875de21d8bcaba88a44f506ce5e
https://pubmed.ncbi.nlm.nih.gov/1358575

A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia

Autor: Ek, Rowinsky, Scott Kaufmann, Sd, Baker, Cb, Miller, Se, Sartorius, Mk, Bowling, Tl, Chen, Rc, Donehower, Sd, Gore

Publikováno v: Europe PubMed Central

The principal objectives of this study were to determine the feasibility of escalating doses of the hydrophilic topoisomerase I (topo I) inhibitor topotecan (TPT) as a 30-min infusion daily for 5 days in adults with refractory or relapsed acute leuke

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::572c32de8076061ede5113a2df5e8323
http://europepmc.org/abstract/med/9816150

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal

Autor: Aa, Adjei, Ii, Budihardjo, Ek, Rowinsky, Tj, Kottke, Pa, Svingen, Ca, Buckwalter, Lb, Grochow, Rc, Donehower, Scott Kaufmann

Publikováno v: Europe PubMed Central

Pyrazoloacridine (PA), an acridine congener that has shown selective toxicity in solid tumor cells, full activity against noncycling and hypoxic cells, and promising activity in a recent Phase I trial, is currently undergoing Phase II testing as a so

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::f1ea332ef7c5dcc7a56fa6fb696bd103
http://europepmc.org/abstract/med/9815747

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue

Autor: Cb, Hendricks, Ek, Rowinsky, Lb, Grochow, Rc, Donehower, Scott Kaufmann

Publikováno v: Europe PubMed Central

Topotecan (TPT, 9-dimethylaminomethyl-10-hydroxycamptothecin) is the first topoisomerase I-directed cytotoxic agent to enter clinical trials in the United States in two decades. The effect of P-glycoprotein (Pgp) overexpression on TPT cytotoxicity wa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4565cd1fd6b752734de5432605b14005
http://europepmc.org/abstract/med/1348448

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial.

Autor: Chen N; Cancer Center, the First Hospital of Jilin University, Changchun, China., Pu C; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Zhao L; Cancer Center, the First Hospital of Jilin University, Changchun, China., Li W; Cancer Center, the First Hospital of Jilin University, Changchun, China., Wang C; Cancer Center, the First Hospital of Jilin University, Changchun, China., Zhu R; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Liang T; Cancer Center, the First Hospital of Jilin University, Changchun, China., Niu C; Cancer Center, the First Hospital of Jilin University, Changchun, China., Huang X; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Tang H; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Wang Y; Cancer Center, the First Hospital of Jilin University, Changchun, China., Yang H; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Jia B; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Jiang X; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Han G; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Wang W; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Chen D; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Wang Y; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Rowinsky EK; Innovative Cellular Therapeutics Inc, Rockville, Maryland., Kennedy E; 80 Horseshoe Pt, Phoenixville, Pennsylvania., Lu VX; Innovative Cellular Therapeutics Inc, Rockville, Maryland., Cui G; Cancer Center, the First Hospital of Jilin University, Changchun, China., Wu Z; Innovative Cellular Therapeutics Co, Ltd, Shanghai, China., Xiao L; Innovative Cellular Therapeutics Inc, Rockville, Maryland., Cui J; Cancer Center, the First Hospital of Jilin University, Changchun, China.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Nov 01; Vol. 10 (11), pp. 1532-1536.